Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Finds FREEDOM From Fingolimod Concerns In Second Phase III, Limits Dose To Play It Safe

This article was originally published in The Pink Sheet Daily

Executive Summary

FREEDOMS clinical trial show lower levels of cancer than first Phase III trial, but Novartis goes one step further by eliminating the highest dose of its oral MS therapy and thus minimizing the side effects associated with FTY720.

You may also be interested in...



Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June

Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.

Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June

Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.

Novartis Holds Lead In Oral MS Space With Fingolimod Filing

Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel